EUVIMEDEUVIMED entdecken
Multizentrische Studie

Limited Effectiveness of IL ‐17 Inhibitors for Anti‐ TNF ‐Induced Psoriasis in Hidradenitis Suppurativa: A Multicenter Retrospective Study

Leonardo Bascón iD, Juan José Lluch-Galcerá iD, Verónica Mora-Fernández, Júlia Verdaguer-Faja iD, Sofía Haselgruber iD, Alejandro Molina-Leyva iD, Maria Sin-Soler, Patricia Garbayo-Salmons iD, Júlia Mercader-Salvans, Vania Lukoviek Araya, Pablo Fernández-Crehuet, Laura Parra-Navarro iD und 6 weitere

International Journal of Dermatology · 2026-12 · 65 (12) · 2515-2523

DOI: 10.1111/ijd.70420 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Dermatology, online erschienen am 14.04.2026. Verfasst von Leonardo Bascón und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital General de Granollers, Barcelona, Spain. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Psoriasis, Interleukin-17. Die Arbeit nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Paradoxical psoriasis (PP) is a known adverse event of anti‐tumor necrosis factor (anti‐TNF) agents in hidradenitis suppurativa (HS), yet evidence regarding its management remains limited. The objective was to assess the effectiveness of interleukin‐17 inhibitors (IL‐17i) in treating anti‐TNF‐induced PP in patients with HS.

Methods

This multicenter retrospective study included 40 adults with HS who developed PP during anti‐TNF therapy and were subsequently treated with IL‐17i. Outcomes for PP were measured using the Physician's Global Assessment (PGA); HS severity was evaluated using the International Hidradenitis Suppurativa Severity Score System (IHS4) and Hurley scores. Paired comparisons were performed using the Wilcoxon signed‐rank or McNemar's test, as appropriate. Multivariate analysis was performed using LASSO‐regularized logistic regression. Missing data were managed by multiple imputation.

Results

Of the patients, 27.5% achieved a clinically meaningful PP response, while 45% experienced worsening. Female sex, older age at HS onset, and prior exposure to secukinumab were associated with nonresponse. Conversely, HS severity improved significantly in 70% of patients ( p < 0.001).

Conclusions

IL‐17i showed limited effectiveness for anti‐TNF‐induced PP in HS, though improvement in hidradenitis was observed. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hidradenitis SuppurativaPsoriasisInterleukin-17HumansFemaleRetrospective StudiesMaleAdultAntibodies, Monoclonal, HumanizedMiddle AgedSeverity of Illness IndexTumor Necrosis Factor-alphaTreatment OutcomeYoung AdultSex FactorsAdalimumab

Stichwörter der Autor:innen

IHS4biologic therapyhidradenitis suppurativainterleukin‐17 inhibitorsparadoxical drug reactionsparadoxical psoriasisphysician's global assessmenttumor necrosis factor‐alpha inhibitors

Substanzen

Interleukin-17Antibodies, Monoclonal, HumanizedTumor Necrosis Factor-alphasecukinumabAdalimumab

Autor:innen und Institutionen

  • Department of Dermatology, Hospital General de Granollers, Barcelona, Spain.
  • Departament de Medicina, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
  • Department of Dermatology, Hospital Universitari Germans Trias i Pujol. IGTP, Barcelona, Spain.
  • Hospital Universitario Virgen de Las Nieves, Ibs, Granada, Spain.
  • Departamento de Dermatología, Universidad de Granada, Ibs, Granada, Spain.
  • Department of Dermatology, Hospital Universitari Parc Taulí, Barcelona, Spain.

ORCID-Profile: Leonardo Bascón, Juan José Lluch-Galcerá, Júlia Verdaguer-Faja, Sofía Haselgruber, Alejandro Molina-Leyva, Patricia Garbayo-Salmons, Laura Parra-Navarro

Zitieren

APA

Bascón, L., Lluch-Galcerá, J. J., Mora-Fernández, V., Verdaguer-Faja, J., Haselgruber, S., Molina-Leyva, A., Sin-Soler, M., Garbayo-Salmons, P., Mercader-Salvans, J., Araya, V. L., Fernández-Crehuet, P., Parra-Navarro, L., Martin-Ezquerra, G., Martin-Poch, A., Carrascosa, J. M., Sampayo-Cordero, M., Romaní, J., & Guilabert Vidal, A. (2026). Limited Effectiveness of IL ‐17 Inhibitors for Anti‐ TNF ‐Induced Psoriasis in Hidradenitis Suppurativa: A Multicenter Retrospective Study. International Journal of Dermatology, 65(12), 2515-2523. https://doi.org/10.1111/ijd.70420

Vancouver

Bascón L, Lluch-Galcerá JJ, Mora-Fernández V, Verdaguer-Faja J, Haselgruber S, Molina-Leyva A, et al. Limited Effectiveness of IL ‐17 Inhibitors for Anti‐ TNF ‐Induced Psoriasis in Hidradenitis Suppurativa: A Multicenter Retrospective Study. International Journal of Dermatology. 2026;65(12):2515-2523. doi:10.1111/ijd.70420

BibTeX
@article{Bascn2026,
  author = {Bascón, Leonardo and Lluch-Galcerá, Juan José and Mora-Fernández, Verónica and Verdaguer-Faja, Júlia and Haselgruber, Sofía and Molina-Leyva, Alejandro and Sin-Soler, Maria and Garbayo-Salmons, Patricia and Mercader-Salvans, Júlia and Araya, Vania Lukoviek and Fernández-Crehuet, Pablo and Parra-Navarro, Laura and Martin-Ezquerra, Gemma and Martin-Poch, Albert and Carrascosa, José Manuel and Sampayo-Cordero, Miguel and Romaní, Jorge and Guilabert Vidal, Antonio},
  title = {Limited Effectiveness of IL ‐17 Inhibitors for Anti‐ TNF ‐Induced Psoriasis in Hidradenitis Suppurativa: A Multicenter Retrospective Study},
  journal = {International Journal of Dermatology},
  year = {2026},
  volume = {65},
  number = {12},
  pages = {2515--2523},
  doi = {10.1111/ijd.70420}
}
Kostenlos starten →